The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of tumor growth rate (TGR) to provide useful clinical information in phase I trials and reveal clear drug-specific profiles.
Charles Ferte
No relevant relationships to disclose
Marianna Fernandez
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Serge Koscielny
No relevant relationships to disclose
Antonin Levy
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Christophe Massard
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose